BORA PHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 713 TWD | -0.28% |
|
-5.19% | +11.58% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,609 | 10,634 | 12,446 | 31,121 | 64,612 | 71,864 | - |
| Enterprise Value (EV) 1 | 6,574 | 12,501 | 13,431 | 31,121 | 64,612 | 77,743 | 73,068 |
| P/E ratio | 18 x | 18.4 x | 16.7 x | 22.7 x | 21.2 x | 22.5 x | 15.3 x |
| Yield | 1.4% | 1.02% | 1.9% | - | - | 1.89% | 1.81% |
| Capitalization / Revenue | 3.67 x | 5.91 x | 2.54 x | 2.97 x | 4.55 x | 3.9 x | 3.35 x |
| EV / Revenue | 4.3 x | 6.95 x | 2.74 x | 2.97 x | 4.55 x | 4.22 x | 3.41 x |
| EV / EBITDA | 14.2 x | 34.1 x | 10.7 x | 13.8 x | 11 x | 12.9 x | 10.4 x |
| EV / FCF | -14.1 x | 438 x | 12.5 x | 17.1 x | - | 33.3 x | 15.9 x |
| FCF Yield | -7.08% | 0.23% | 7.99% | 5.86% | - | 3.01% | 6.29% |
| Price to Book | 3.33 x | 4.29 x | 3.99 x | 6.87 x | - | 6.55 x | 4.82 x |
| Nbr of stocks (in thousands) | 91,161 | 96,417 | 96,687 | 97,524 | 101,115 | 100,791 | - |
| Reference price 2 | 61.52 | 110.3 | 128.7 | 319.1 | 639.0 | 713.0 | 713.0 |
| Announcement Date | 20-03-16 | 21-03-29 | 22-03-09 | 23-03-20 | 24-03-07 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,529 | 1,800 | 4,900 | 10,494 | 14,200 | 18,426 | 21,456 |
| EBITDA 1 | 464.5 | 367.1 | 1,256 | 2,263 | 5,855 | 6,007 | 6,993 |
| EBIT 1 | 344.8 | 226.1 | 1,046 | 1,922 | 5,249 | 5,536 | 6,847 |
| Operating Margin | 22.55% | 12.56% | 21.35% | 18.32% | 36.97% | 30.04% | 31.91% |
| Earnings before Tax (EBT) 1 | 325.4 | 595.4 | 1,024 | 1,840 | 4,064 | 4,346 | 6,184 |
| Net income 1 | 305 | 578.4 | 749.7 | 1,392 | 3,030 | 3,215 | 4,706 |
| Net margin | 19.95% | 32.14% | 15.3% | 13.26% | 21.34% | 17.45% | 21.93% |
| EPS 2 | 3.411 | 5.989 | 7.703 | 14.09 | 30.20 | 31.71 | 46.52 |
| Free Cash Flow 1 | -465.6 | 28.56 | 1,073 | 1,822 | - | 2,337 | 4,597 |
| FCF margin | -30.44% | 1.59% | 21.9% | 17.36% | - | 12.68% | 21.43% |
| FCF Conversion (EBITDA) | - | 7.78% | 85.43% | 80.54% | - | 38.9% | 65.73% |
| FCF Conversion (Net income) | - | 4.94% | 143.14% | 130.92% | - | 72.68% | 97.69% |
| Dividend per Share 2 | 0.8635 | 1.123 | 2.449 | - | - | 13.50 | 12.88 |
| Announcement Date | 20-03-16 | 21-03-29 | 22-03-09 | 23-03-20 | 24-03-07 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,189 | 1,150 | 1,117 | 1,355 | 2,724 | 5,298 | 4,781 | 3,139 | 3,075 | 3,206 | 2,857 | 5,062 | 5,202 | 5,436 | 5,225 |
| EBITDA 1 | 272.4 | 237.7 | 305 | 421.5 | - | - | 1,681 | 1,485 | 1,370 | 1,320 | 1,293 | 1,609 | 1,788 | 2,037 | - |
| EBIT 1 | 216.8 | 186.3 | 251.6 | 369.4 | 643.3 | 657.8 | 1,547 | 1,347 | 1,219 | 1,320 | 1,004 | 1,411 | 1,548 | 1,588 | 1,526 |
| Operating Margin | 18.24% | 16.2% | 22.52% | 27.27% | 23.62% | 12.42% | 32.37% | 42.91% | 39.64% | 41.18% | 35.12% | 27.87% | 29.75% | 29.2% | 29.21% |
| Earnings before Tax (EBT) 1 | 205.9 | 182.3 | 253 | 369.1 | 782 | 435.9 | 1,442 | 1,019 | 923 | 679.7 | 699 | 1,096 | 1,233 | 1,274 | 1,276 |
| Net income 1 | 137.7 | 140.1 | 179.2 | 240 | 568.9 | 403.9 | 1,039 | 692 | 733.2 | 565.6 | 510.5 | 808 | 911.5 | 942 | 933 |
| Net margin | 11.58% | 12.18% | 16.04% | 17.72% | 20.88% | 7.62% | 21.74% | 22.05% | 23.84% | 17.64% | 17.87% | 15.96% | 17.52% | 17.33% | 17.86% |
| EPS 2 | 1.413 | 1.420 | 1.826 | 2.463 | 5.813 | 4.003 | 10.49 | 8.810 | 7.280 | 6.090 | 5.030 | 7.960 | 8.975 | 9.280 | 9.220 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-11 | 22-03-09 | 22-05-10 | 22-08-12 | 22-11-14 | 23-03-20 | 23-05-12 | 23-08-14 | 23-11-09 | 24-03-07 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 965 | 1,867 | 985 | - | - | 5,879 | 1,204 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.078 x | 5.087 x | 0.7841 x | - | - | 0.9787 x | 0.1721 x |
| Free Cash Flow 1 | -466 | 28.6 | 1,073 | 1,822 | - | 2,337 | 4,597 |
| ROE (net income / shareholders' equity) | 20.5% | 28.1% | 26.7% | 36.2% | - | 27.4% | 40.6% |
| ROA (Net income/ Total Assets) | 10.9% | 11.1% | 10.4% | 9.24% | - | 11.1% | 12.9% |
| Assets 1 | 2,807 | 5,192 | 7,188 | 15,067 | - | 28,895 | 36,526 |
| Book Value Per Share 2 | 18.50 | 25.70 | 32.20 | 46.40 | - | 109.0 | 148.0 |
| Cash Flow per Share 2 | 2.580 | 1.840 | 12.70 | - | - | 35.30 | 33.80 |
| Capex 1 | 697 | 149 | 163 | 188 | - | 280 | 233 |
| Capex / Sales | 45.6% | 8.29% | 3.34% | 1.79% | - | 1.52% | 1.08% |
| Announcement Date | 20-03-16 | 21-03-29 | 22-03-09 | 23-03-20 | 24-03-07 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
713
TWD
Average target price
865
TWD
Spread / Average Target
+21.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.58% | 2.22B | |
| +30.38% | 695B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 330B | |
| +3.73% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +7.68% | 168B |
- Stock Market
- Equities
- 6472 Stock
- Financials Bora Pharmaceuticals Co., LTD.